HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA today announced that Octagam 10% [Immune Globulin Intravenous (Human) 10% (100 mg/mL) Liquid Preparation] is available for ordering within the U.S.
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% for the treatment of adults with chronic Immune Thrombocytopenic Purpura (ITP), a platelet disorder that can result in easy or excessive bruising and bleeding. In a pivotal clinical study of adults with chronic ITP, Octagam 10% delivered rapid and sustained results without compromising tolerability. The most serious drug-related adverse event reported with Octagam 10% treatment was a headache.1,2
Help employers find you! Check out all the jobs and post your resume.
